



COPY OF PAPERS
ORIGINAL FILED

#16/K.T.
5/18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Suppl.
I.D.S.

In re Application of: Andrew S. Greenberg Application No: 09/690,647 Filed: October 17, 2000 For: <i>Methods for Treating and Preventing Insulin Resistance and Related Disorders</i>	Examiner: Schmidt, M. Art Unit: 1635 Attorney Ref. No: TUV-005.01
--	---

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on April 18, 2002.

Michael P. Hub

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97(c)

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED
MAY 1 2002
1635

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicant and/or his attorney in compliance with the requirements of 37 CFR 1.56. Copies of these documents ("EA" - "EF") are also being submitted herewith.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that the cited documents are material or constitute "prior art." If the Examiner applies the listed documents as prior art against any claim in the

application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of said document.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the referenced documents be applied against the claims of the present application.


As a First Office Action on the merits has been received, please charge the applicable amount due of \$180.00 as required under 37 C.F.R. § 1.17(p) to our **Deposit Account No. 06-1448**.

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1000.

Respectfully Submitted,

Date: April 18, 2002

Customer No. 25181
Patent Group
Foley, Hoag & Eliot LLP
One Post Office Square
Boston, MA 02109-2170


Isabelle M. Clauss, Ph.D.
Reg. No. 47,326
Attorney for Applicant

Form PTO-1449

INFORMATION DISCLOSURE CITATION**IN AN APPLICATION**
(Use several sheets if necessary)

Docket Number (Optional)

TUV-005 01

Application Number

09/690,647

Applicant

Andrew S. Greenberg

Filing Date

10:17:00

Group Art Unit

1635

APR 29 2002

PATENT & TRADEMARK OFFICE

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

EA	Engelman et al. (2000), <i>Tumor Necrosis Factor α-Mediated Insulin Resistance, but Not Dedifferentiation, is Abrogated by MEK1/2 Inhibitors in 3T3-L1 Adipocytes</i> , MOLECULAR ENDOCRINOLOGY 14(10):1557.
EB	Souza et al. (1998), <i>Overexpression of Perilipin A and B Blocks the Ability of Tumor Necrosis Factor α to Increase Lipolysis in 3T3-L1 Adipocytes</i> , J. BIOL. CHEM. 273(38):24665.
EC	Edelstein Rosenbaum and Greenberg (1998), <i>The Short- and Long-Term Effects of Tumor Necrosis Factor-α and BRL 49653 on Peroxisome Proliferator-Activated Receptor (PPAR) γ2 Gene Expression and Other Adipocyte Genes</i> , MOLECULAR ENDOCRINOLOGY 12(8):1150.
ED	Greenberg et al. (1993), <i>Isolation of cDNAs for Perilipins A and B: Sequence and Expression of Lipid Droplet-Associated Proteins of Adipocytes</i> , PROC. NATL. ACAD. SCI. USA 90:12035.
EE	Egan et al. (1992), <i>Mechanism of Hormone-Stimulated Lipolysis in Adipocytes: Translocation of Hormone-Sensitive Lipase to the Lipid Storage Droplet</i> , PROC. NATL. ACAD. SCI. USA 89:8537.
EF	Camp et al. (1999), <i>c-Jun N-Terminal Kinase Phosphorylates Peroxisome Proliferator-Activated Receptor-γ1 and Negatively Regulates its Transcriptional Activity</i> , ENDOCRINOLOGY 140(1):392.